Association Between Plasminogen Activator Inhibitor-1-675 4G/5G Insertion/Deletion Polymorphism and Chronic Obstructive Pulmonary Disease

• Published in: Chronic obstructive pulmonary disease Vol. 13; no. 6; p. 756
• Main Authors: Essa, Enas S, El Wahsh, Rabab A
• Format: Journal Article
• Language: English
• Published: England 01-11-2016
• Subjects: Adult; Aged; Case-Control Studies; Genes, Dominant; Genes, Recessive; Genotype; Humans; INDEL Mutation; Male; Middle Aged; Plasminogen Activator Inhibitor 1 - genetics; Polymorphism, Genetic; Promoter Regions, Genetic; Pulmonary Disease, Chronic Obstructive - genetics; Smoking; PAI-1 4G/5G; Association; COPD
• ISSN: 1541-2563
• DOI: 10.3109/15412555.2016.1168392

Molecular pathology of chronic obstructive pulmonary disease (COPD) is still being investigated to discover relationships with disease pathogenesis. Evidence of plasminogen activator inhibitor-1 (PAI-1) overexpression in the sputum and the blood of COPD patients is growing. We aimed to investigate the potential relation between PAI-1 promoter 4G/5G insertion/deletion polymorphism and COPD development. In a case-control study, we genotyped 117 COPD patients and 160 control subjects for PAI-1 promoter 4G/5G polymorphism by an allele-specific polymerase chain reaction analysis. All subjects were male smokers. In the co-dominant model, there was a significant difference in the distribution of 5G/5G, 4G/5G and 4G/4G genotypes between COPD patients and controls (p = 0.002). In the recessive model, carriers of 4G/4G genotype were significantly higher in COPD patients than controls (p = 0.01). Carriers of 4G/4G genotype were at higher risk to develop COPD than those carrying 5G/5G or 4G/5G genotypes (crude odds ratio (OR) = 2.10, 95% confidence interval (CI) = 1.19-3.73, adjusted OR = 2.5, 95% CI = 1.22-3.99). In conclusion, PAI-1 4G/5G genetic variations are associated with COPD development in males.